Most, but not all, anesthetics are known to facilitate GABA A receptor activity 67 thereby enhancing inhibitory synaptic transmission. Modulation of GABA A receptors in 68 this manner is known to be an important part of the mechanism of action for many 69
anesthetics. More recent studies, however, have shown that general anesthetics can 70 influence a number of voltage and ligand gated ion channels (Campagna et made it difficult to isolate the release machinery in many of these experiments. 79
In the present study we set out to determine if the clinically used volatile anesthetic, 80 isoflurane, directly influences the mammalian neurotransmitter release machinery. To 81 accomplish this, it is necessary to observe the effect of isoflurane on evoked 82 neurotransmitter release independent of anesthetic modulation of channels and receptors. 83
To prevent actions of anesthetics on channels or receptors from altering neurotransmitter 84 release, we used experimental paradigms that kept membrane potential constant, but which 85 allowed [Ca 2+ ] i to be elevated by a known amount. These paradigms allowed us to probe 86 interactions between anesthetics and the release machinery directly. We observed that 87 
94
This mutant syntaxin is missing part of the H3 domain and the entire transmembrane 95 domain; the mutant syntaxin also includes 10 novel amino acids on the carboxy-terminus.
96
The md130A mutation blocked the behavioral effects of isoflurane in C. elegans (van 97 Swinderen et al. 1999 ). Overexpression of md130A in PC12 cells completely blocked 98 isoflurane's ability to inhibit the neurotransmitter release machinery. This data suggests a 99 possible role for syntaxin 1A as an intermediary in isoflurane's ability to inhibit 100 neurotransmitter release. 101
102

Materials and Methods
103
PC12 and neuronal cell culture 104 PC12 cells were grown on collagen-coated 10 cm Petri dishes in culture medium 105 that consisted of RPMI-1640, 10% heat-inactivated horse serum, 5% fetal bovine serum, 2 106 mM glutamine, and 10 µg/ml gentamicin in a humidified 7% CO 2 incubator at 37ºC. 107
Culture medium was replaced every other day and cells were passaged once per week. 108
Cells were replated on poly-lysine coated glass coverslips 24 hours prior to recording. 109
Hippocampal neuron cultures were prepared from E18 Sprague-Dawley rats as previously 110 -free solution (1), the cell was permeabilized with 20 µM digitonin (Ca 2+ -free) for 25 126 sec (2), and then stimulated for 2-3 min with a solution containing 100 µM Ca 2+ (3). The 127 cell was allowed to recover for 2 min in Ca 2+ -free media (4), and the cycle began again at 128 step (2). Cells were stimulated 4-5 times in this way. In drug treated cells isoflurane or the 129 non-immobilizer, F6, was introduced into the bath 25 sec prior to stimulation and was 130 present throughout the recording. This was done in order to maximize drug exposure time. 131
The stimulation step (3) producing the greatest amount of release was analyzed. The 132 recording solutions had standard compositions previously described in (Grabner et al. 133 2005) . 134
135
Optical measurement of evoked RH414 release
136
Coverslips containing live rat hippocampal neurons were briefly rinsed in HBSS 137 before being placed in a 60 mM KCl loading solution containing 10 μM RH414 (Molecular 138 probes, Eugene, OR) for 75 sec. The coverslips were then put back into HBSS for 1-5 min. 139 RH414 loaded synapses were observed using an Olympus IX81 inverted microscope 140 through a U Plan APO 60x water objective (0.512 um/pixel). 530-550 nm light from a high 141 power 100W Hg arc lamp was used for excitation, and emitted light was filtered through a 142 590LP filter. Images were captured using MetaMorph. condition and compared to that of nerve terminals exposed to isoflurane. A student's t-test 161 was again used to assess differences between the two conditions. Tau values were 162 determined by fitting fluorescent intensity plots with a second-order exponential decay 163 function, y=y 0 ] i may 242 rise to levels above 100 μM at the vesicle (Llinas et al. 1992 ). To mimic these levels in our 243 experiments, evoked neurotransmitter release was elicited by exposing digitonin-244 permeabilized cells to 100 μM Ca 2+ , for 2 min (as indicated), in the absence of isoflurane 245 (Fig. 1A) or in the presence of isoflurane (0.5 mM; Fig. 1B ). The amperometric trace in the 246 presence of isoflurane contained many fewer amperometric events. Control cells had an 247 average of 94 ± 13 (n = 25) amperometric events during a 2 min stimulation while cells 248 exposed to isoflurane (0.5 mM) had 58 ± 11 (n = 24) events (mean ± SEM; fig. 1C ). This 249 38% reduction in the number of amperometric events was significant (P = 0.049). These 250 data suggest that isoflurane inhibits the neurotransmitter release machinery at a clinically 251 relevant concentration by reducing the number of vesicles released. 252
[On each day of recording, amperometric measurements were made from a similar number 253 of experimental and control cells. This strategy reduces cell-to-cell variation]. 254
Isoflurane was also found to inhibit the neurotransmitter release machinery in a 255 dose-dependent fashion over a range of concentrations (0.3, 0.5, 1, 2, and 3 mM) that 256 include the clinically relevant range (0.3 -1 mM). Isoflurane at 0.3, 1, 2, and 3 mM 257 reduced the number of amperometric events per 2 min stimulation by 27, 52, 64 and 54%, 258 respectively. Fig. 1D plots the number of amperometric events observed as a function of 259 isoflurane concentration. These data were fit with a standard dose-response equation (see 260 legend). The best possible fit of the data suggests the effects of isoflurane on the 261 neurotransmitter release machinery saturate at concentrations > 1 mM, which maximally 262 reduce neurotransmitter release by ~70%. The inset plots the same data on a linear scale to 263 better illustrate the saturation of the response to isoflurane. 1 mM, 2 mM and 3 mM 264 isoflurane inhibited neurotransmitter release to the same extent. The EC 50 provided by the 265 fitting function was 0.38 mM isoflurane. Here, the EC 50 refers to the concentration at which 266 isoflurane reached 50% of its maximal inhibition (~70%). The MAC (minimum alveolar 267 concentration required for immobility in response to a noxious stimulus in 50% of trials 268 (Eger et al. 1965 )) equivalent of the isoflurane used in this study has been reported to be 269 ~0.3 mM (Franks and Lieb 1996) at 25°C. Dose-dependent effects on quantal amplitude or 270 kinetics were not observed (data not shown). Together, these data indicate that isoflurane 271 has a statistical and biologically important dose-dependent effect on the release machinery 272 at concentrations spanning this anesthetic's clinically effective range. 273
To ensure that isoflurane inhibited the neurotransmitter release machinery and not 274 digitonin-permeabilization a patch pipette was used to dialyze cells with a 100 µM Ca interaction between isoflurane and syntaxin 1A. Surprisingly, cells expressing md130A 471 produced more amperometric events when they were stimulated in the presence of 472 isoflurane than in the absence of isoflurane (see Fig. 5B ). An increase in amperometric 473 event number was also observed in permeabilized PC12 cells exposed to the non-474 immobilizer, F6 (see fig. 3 ). While in both cases increases in neurotransmitter release failed 475 to reach significance, increasing the number of recordings in these experiments may 476 ultimately lead to significant results. Thus, in blocking isoflurane's ability to inhibit 477 neurotransmitter release with md130A, we may have unmasked a weaker stimulatory 478 effect. It is also interesting that overexpression of md130A was found to completely block 479 the effects of isoflurane on the neurotransmitter release machinery despite the presence of 480 endogenous syntaxin 1A. One possible explanation is md130A operates in a dominant 481 fashion with regards to endogenous syntaxin 1A. Additional study will be necessary to test 482 these hypotheses. 483
The details of syntaxin's involvement in the response to isoflurane remain unclear. Crowder and colleagues whereby isoflurane inhibits the recruitment of the syntaxin 500 activator, UNC-13, to the plasma membrane, thereby reducing syntaxin 1A activation 501 (Metz et al. 2007 ). This group goes on to speculate that the md130A mutant may bind to 502 UNC-13, preventing the association of isoflurane with the syntaxin activator. Our data is 503 consistent with this model as well. In this scenario the potential of md130A to act 504 dominantly may also be explained as a consequence of increased motility. A soluble 505 md130A might preferentially bind to soluble (unactivated) UNC-13 and prevent the 506 binding of anesthetic molecules to this syntaxin 1A activator. An md130A/UNC-13 507 association prior to the recruitment of UNC-13 to the plasma membrane (activation) may 508 "protect" this syntaxin 1A activator from anesthetic molecules until md130A can be 509 replaced with endogenous syntaxin. Additional study will undoubtedly be necessary to test 510 these hypotheses or to determine whether other as yet unidentified release machinery 511 proteins play a role in the response to isoflurane. 512
Regardless of how isoflurane interacts with the release machinery, this mechanism 513 is likely to operate in humans due to the highly conserved nature of the neurotransmitter 514 release machinery among a variety of species that span invertebrates to mammals. While 515 our data seems to suggest biologically relevant inhibition of the release machinery by 516 isoflurane, it is unclear at the present time as to whether this mechanism participates in the 517 production of the anesthetic state. In the future it will be necessary to generate knockout or 518 transgenic animals in which the effects of anesthetics on the release machinery are blocked 519 in order to determine the relative contribution of this mechanism to the production of 520 anesthesia. 
